Is There a Perfect Model of Decision Making?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

I think there'll be certain experiments that you want to run locally, especially things that you're developing. And then maybe at some point you can kind of package that up and have someone else roun it for you. But i think you're going to see all three in the future. The purely virtual stuff, we still have aways to go on. That's absolutely true. I would say, ok, what what is maybe an under appreciated aspect of being able to have a fully virtual kind of experiment? There's no such thing as a perfect model. All models are wrong. Some are useful. S like, we will use whatever technology is necessary to improve scientific decision making. Whatever

There has been a massive expansion in data emanating from bio labs, and that means next-generation AI algorithms and machine learning models finally have the grist to transform the future trajectories of biology and health therapies. Yet, there’s a key translation challenge: how do you get computer scientists and biologists — two types of specialists with very different training — to collaborate with each other effectively?

Two groups, Bits in Bio and Nucleate, have independently spearheaded new ways of bringing all people interested in tech and biology together to share best practices and think through patterns of startup inception and growth. Today, we bring the founders and early champions of those two groups together for the first time in person to talk about their work.

Joining us first is Michael Retchin, a PhD student at Weill Cornell Medicine and the founder of Nucleate, a free and collaborative student-run organization that facilitates the formation of pioneering life science companies. Second, we have Nicholas Larus-Stone, the first software engineering hire at Octant.bio, a Lux-backed synthetic biology startup, as well as the founder of Bits in Bio. Finally, joining “Securities” host Danny Crichton is Lux biotech investor Shaq Vayda.

We talk about where tech + bio (versus “biotech”) is coming from, how the two community leaders launched and grew their respective organizations, the coming challenges in biology, and our speculative dreams for the future of what biology could look like in the years ahead.